ZA200203648B - A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt. - Google Patents
A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt. Download PDFInfo
- Publication number
- ZA200203648B ZA200203648B ZA200203648A ZA200203648A ZA200203648B ZA 200203648 B ZA200203648 B ZA 200203648B ZA 200203648 A ZA200203648 A ZA 200203648A ZA 200203648 A ZA200203648 A ZA 200203648A ZA 200203648 B ZA200203648 B ZA 200203648B
- Authority
- ZA
- South Africa
- Prior art keywords
- vessel
- make
- delivery
- atorvastatin
- methyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 27
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title claims description 24
- 229960005370 atorvastatin Drugs 0.000 title claims description 24
- 159000000007 calcium salts Chemical class 0.000 title claims description 15
- -1 atorvastatin trihydrate Chemical class 0.000 title claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 27
- 239000002002 slurry Substances 0.000 claims description 18
- 239000013078 crystal Substances 0.000 claims description 17
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 9
- 239000001639 calcium acetate Substances 0.000 claims description 9
- 229960005147 calcium acetate Drugs 0.000 claims description 9
- 235000011092 calcium acetate Nutrition 0.000 claims description 9
- 239000011877 solvent mixture Substances 0.000 claims description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 22
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 15
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 15
- 229960001770 atorvastatin calcium Drugs 0.000 description 15
- 238000002425 crystallisation Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000011159 matrix material Substances 0.000 description 12
- 239000010410 layer Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 239000012535 impurity Substances 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 6
- UOENAPUPIPQFOY-UHFFFAOYSA-J dicalcium tetraacetate hydrate Chemical compound O.C(C)(=O)[O-].[Ca+2].[Ca+2].C(C)(=O)[O-].C(C)(=O)[O-].C(C)(=O)[O-] UOENAPUPIPQFOY-UHFFFAOYSA-J 0.000 description 5
- OUCSEDFVYPBLLF-KAYWLYCHSA-N 5-(4-fluorophenyl)-1-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-n,4-diphenyl-2-propan-2-ylpyrrole-3-carboxamide Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H]2OC(=O)C[C@H](O)C2)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 OUCSEDFVYPBLLF-KAYWLYCHSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 150000002596 lactones Chemical class 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 2
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011268 mixed slurry Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960004829 atorvastatin calcium trihydrate Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000005649 metathesis reaction Methods 0.000 description 1
- 150000002894 organic compounds Chemical group 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IE9900132 | 1999-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200203648B true ZA200203648B (en) | 2003-02-10 |
Family
ID=11042528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200203648A ZA200203648B (en) | 1999-12-17 | 2002-05-08 | A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt. |
Country Status (13)
Country | Link |
---|---|
US (1) | US6600051B2 (de) |
EP (2) | EP1237865B1 (de) |
JP (1) | JP2003517038A (de) |
AT (1) | ATE309985T1 (de) |
AU (1) | AU776613B2 (de) |
CA (1) | CA2388226A1 (de) |
DE (1) | DE60024133T2 (de) |
ES (1) | ES2252088T3 (de) |
HU (1) | HUP0203708A3 (de) |
IL (2) | IL149087A0 (de) |
MX (1) | MXPA02004078A (de) |
WO (1) | WO2001044180A1 (de) |
ZA (1) | ZA200203648B (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69616808T2 (de) | 1995-07-17 | 2002-05-29 | Warner Lambert Co | Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrol-1-heptancarbonsäure hemi calcium salz (atorvastatin) |
US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
PL367943A1 (en) * | 2001-06-29 | 2005-03-07 | Warner-Lambert Company Llc | Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
US7074818B2 (en) * | 2001-07-30 | 2006-07-11 | Dr. Reddy's Laboratories Limited | Crystalline forms VI and VII of Atorvastatin calcium |
US20060020137A1 (en) * | 2001-11-29 | 2006-01-26 | Limor Tessler | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
DE03713610T1 (de) * | 2002-02-15 | 2005-10-20 | Teva Pharma | Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium |
KR20090045420A (ko) | 2002-02-19 | 2009-05-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 아토르바스타틴 헤미-칼슘 용매화합물의 탈용매화 |
WO2004050618A2 (en) * | 2002-11-28 | 2004-06-17 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
EP1424324A1 (de) * | 2002-11-28 | 2004-06-02 | Teva Pharmaceutical Industries Limited | Kristalline Form F von Atorvastatin |
JP2007536373A (ja) | 2004-05-05 | 2007-12-13 | ファイザー・プロダクツ・インク | アトルバスタチンの塩形態 |
WO2006008091A2 (en) * | 2004-07-16 | 2006-01-26 | Lek Pharmaceuticals D.D. | Oxidative degradation products of atorvastatin calcium |
BRPI0610344A2 (pt) * | 2005-12-13 | 2016-11-29 | Teva Pharma | forma cristalizada do atorvastatin hemi-calcium, processo para sua preparação, produto famacêutico derivado e seu uso medicinal |
WO2008157681A1 (en) * | 2007-06-20 | 2008-12-24 | Coating Excellence International Llc | Flat bottom bag |
GR1006173B (el) * | 2007-12-21 | 2008-11-26 | Ανωνυμος Φαρμακευτικη-Χημικη Βιομηχανια Medichromα.Ε. | Χημικη συνθεση του (3r, 5r) - διυδροξυ - 7 - [2-(4-φθοροφαινυλ) - 5 - σοπροπυλ - 3 - φαινυλ - 4 - φαινυλκαρβαμοϋλο - πυρρολυλο - τριενυδρο - επτανοϊκου ασβεστιου, εφαρμογη φαρμακευτικου σκευασματος και παραγωγικη διαδικασια |
CN103483238B (zh) * | 2013-08-20 | 2014-12-31 | 蚌埠丰原医药科技发展有限公司 | 阿托伐他汀钙三水合物的制备方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5216174A (en) | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5003080A (en) | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5103024A (en) | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5248793A (en) | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5155251A (en) | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
DE69616808T2 (de) * | 1995-07-17 | 2002-05-29 | Warner Lambert Co | Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrol-1-heptancarbonsäure hemi calcium salz (atorvastatin) |
US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
HU226465B1 (en) | 1996-07-29 | 2008-12-29 | Warner Lambert Co | Improved process for the synthesis of protected esters of (s)-3,4-dihydroxybutyric acid |
IL135562A (en) | 1997-12-19 | 2005-08-31 | Warner Lambert Exp Ltd | Process for the synthesis of cis-1,3-diols and a synergistic combination of trialkylborane and dialkylalkoxyborane for such synthesis |
-
2000
- 2000-12-18 HU HU0203708A patent/HUP0203708A3/hu unknown
- 2000-12-18 EP EP00988991A patent/EP1237865B1/de not_active Expired - Lifetime
- 2000-12-18 JP JP2001545268A patent/JP2003517038A/ja active Pending
- 2000-12-18 AT AT00988991T patent/ATE309985T1/de not_active IP Right Cessation
- 2000-12-18 AU AU25440/01A patent/AU776613B2/en not_active Ceased
- 2000-12-18 ES ES00988991T patent/ES2252088T3/es not_active Expired - Lifetime
- 2000-12-18 CA CA002388226A patent/CA2388226A1/en not_active Abandoned
- 2000-12-18 IL IL14908700A patent/IL149087A0/xx active IP Right Grant
- 2000-12-18 EP EP05076123A patent/EP1584616A1/de not_active Withdrawn
- 2000-12-18 DE DE60024133T patent/DE60024133T2/de not_active Expired - Fee Related
- 2000-12-18 MX MXPA02004078A patent/MXPA02004078A/es active IP Right Grant
- 2000-12-18 WO PCT/IE2000/000150 patent/WO2001044180A1/en active IP Right Grant
-
2002
- 2002-04-11 IL IL149087A patent/IL149087A/en not_active IP Right Cessation
- 2002-05-08 ZA ZA200203648A patent/ZA200203648B/en unknown
- 2002-06-14 US US10/172,051 patent/US6600051B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
IL149087A (en) | 2006-12-31 |
ES2252088T3 (es) | 2006-05-16 |
DE60024133T2 (de) | 2006-08-03 |
JP2003517038A (ja) | 2003-05-20 |
MXPA02004078A (es) | 2002-10-11 |
EP1237865A1 (de) | 2002-09-11 |
AU2544001A (en) | 2001-06-25 |
EP1237865B1 (de) | 2005-11-16 |
HUP0203708A3 (en) | 2003-11-28 |
US20020156294A1 (en) | 2002-10-24 |
CA2388226A1 (en) | 2001-06-21 |
DE60024133D1 (de) | 2005-12-22 |
EP1584616A1 (de) | 2005-10-12 |
WO2001044180A1 (en) | 2001-06-21 |
ATE309985T1 (de) | 2005-12-15 |
US6600051B2 (en) | 2003-07-29 |
HUP0203708A2 (hu) | 2003-03-28 |
IL149087A0 (en) | 2002-11-10 |
AU776613B2 (en) | 2004-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1237865B1 (de) | Herstellungsverfahren auf industrieller basis von atorvastatin trihydrat hemi-kalziumsalz in kristalliner form | |
CA2220455C (en) | Novel process for the production of amorphous [r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) | |
JP3296563B2 (ja) | 形態▲III▼の結晶性の(R−(R▲上*▼,R▲上*▼))−2−(4−フルオロフェニル)−β,δ−ジヒドロキシ−5−(1−メチル−エチル)−3−フェニル−4−((フェニルアミノ)カルボニル)−1H−ピロール−1−ヘプタン酸ヘミカルシウム塩(アトルバスタチン) | |
AU780247B2 (en) | A process for producing crystalline atorvastatin calcium | |
NO309898B1 (no) | Krystallinsk form I [R-(R*,R*)]-2-(4-fluorfenyl)- <beta>,<delta>-dihydroksy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptansyrehemikalsiumsalt | |
KR20020073137A (ko) | 비결정형의 아토르바스타틴의 제조방법 | |
WO2006048894A1 (en) | Novel crystalline forms of atorvastatin calcium and processes for preparing them. | |
IE20001034A1 (en) | A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt | |
IES20001035A2 (en) | A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt | |
IE84049B1 (en) | A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt | |
EP0848704B2 (de) | Kristalline form iii des hemi calcium salzes von ¬r-(r*,r*) -2-(4-fluorphenyl)-beta-delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-¬(phenylamino)carbonyl -1h-pyrrol-1-heptansäure (atorvastatin) | |
IES20001033A2 (en) | An improved process for producing crystalline atorvastation calcium | |
IE20001032A1 (en) | An improved process for producing crystalline atorvastatin calcium | |
JP2003073354A (ja) | 形態IIIの結晶性の(R−(R*,R*))−2−(4−フルオロフェニル)−β,δ−ジヒドロキシ−5−(1−メチル−エチル)−3−フェニル−4−((フェニルアミノ)カルボニル)−1H−ピロール−1−ヘプタン酸ヘミカルシウム塩(アトルバスタチン) |